Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 12 - 01 save search
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
Published: 2021-12-01 (Crawled : 22:00) - vbivaccines.com
VBIV | $0.6001 -1.46% -1.48% 180K
|
Health Technology
|
| O: -4.17%
H: 0.33%
C: -9.36%
AGEN | News | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 1.68%
H: 0.99%
C: -0.33%
phase 2 immunotherapy therapy vaccine phase 2b
Innovative cardiovascular treatments: Top pharmacotherapy breakthroughs at AHA21
Published: 2021-12-01 (Crawled : 18:00) - clarivate.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
treatment cardio cardiovascular therapy
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer
Published: 2021-12-01 (Crawled : 16:00) - biospace.com/
FUSN | $21.24 0.0% 330K
|
Health Technology
|
| O: 1.19%
H: 0.0%
C: -6.37%
DFFN 4 | $6.6 11.68% -34.32% 350K
|
Health Technology
|
| O: -1.42%
H: 1.88%
C: -6.37%
treatment patent therapy cancer iot
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
RARE | $43.38 -1.65% -1.68% 770K
|
Health Technology
|
| O: 0.25%
H: 3.1%
C: 0.98%
treatment disease phase 1 therapy
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
LIVN | $52.8 1.79% 1.76% 540K
|
Health Technology
|
| O: -0.48%
H: 2.24%
C: -0.98%
conference therapy depression train
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)
Published: 2021-12-01 (Crawled : 14:00) - beyondspringpharma.com
BYSI | $1.81 -2.16% -2.21% 56K
|
Health Technology
|
| O: -55.97%
H: 8.19%
C: -15.87%
new drug fda application drug therapy plinabulin
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-12-01 (Crawled : 12:30) - globenewswire.com
CMPS | $8.41 -1.41% -1.43% 290K
|
Health Technology
|
| O: 6.29%
H: 0.0%
C: -8.02%
treatment comp360 trial positive results positive therapy results depression psilocybin
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
Published: 2021-12-01 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
technology acne immunotherapy therapy biotech vaccine iot
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.